Outcome in women undergoing uterine artery embolization for arterio-venous malformation diagnosed post-pregnancy-A retrospective study

Abstract

Objective: To analyse the outcome of patients with symptomatic arterio-venous malformation (AVM), formed following pregnancy and managed by uterine artery embolization (UAE).

Materials and Methods: This retrospective study was conducted after ethical approval and included 15 patients presenting with abnormal uterine bleeding following pregnancy, who were suspected to have an AVM which later was confirmed by angiography and managed with UAE. Presenting symptoms, post-UAE complications and subsequent fertility outcomes were noted. Follow-up period ranged from 6 months to 2.5 years.

Results: The mean age was 28.4±3.82 years and mean parity was 1.3. Out of 15 cases, 9 (60%) presented after abortion, 4 (26.6%) after normal vaginal delivery and 2 (13.3%) after cesarean delivery; of these 10/15 (66.7%) patients had a history of curettage. The most common presenting symptom was continuous bleeding per-vaginum since the antecedent pregnancy in 9/15 (60%) patients and 6/15 (40%) patients had irregular bleeding. The mean duration of symptoms was 91±85.7 (30-360) days. For UAE, embolic agents used were polyvinyl alcohol (PVA) particles (300-500 μm) in 2 (13.3%), 30% glue injection in 3 (20%), the combination of PVA with glue injection in 4 (26.6%) and PVA with gelfoam in 6 (40%) patients. After UAE, bleeding responded within 3.6±0.97 (3-6) days in all but one patient who required repeat UAE one month later. All women resumed their normal menstrual cycle in 31.3±5.2 (24-42) days. Ten patients desired conception, of whom 5 (50%) conceived within 13.2±5.1 (6-19) months after UAE. Two women carried pregnancy to term, one underwent preterm cesarean for growth restriction with oligohydramnios. One patient had postpartum hemorrhage, which was managed medically. One had spontaneous abortion at 6 weeks gestation and the other is 13 weeks pregnant at present.

Conclusion: UAE is an effective treatment modality for the management of symptomatic post-pregnancy AVMs.

Keywords: Uterine artery embolization, arteriovenous malformation, post-pregnancy, outcomes

Öz

Amaç: Gebelikten sonra oluşan ve uterin arter embolizasyonu (UAE) ile tedavi edilen semptomatik arterio-venöz malformasyonu (AVM) hastaların sonuçlarını analiz etmek.

Gereç ve Yöntemler: Bu retrospektif çalışma, etik onay alındıktan sonra yapıldı ve gebelik sonrası anormal uterin kanama ile başvuran, AVM’i olduğundan şüphelenilen ve daha sonra anjiyografi ile doğrulanmış ve UAE ile tedavi edilen 15 hastayı içeriyoordu. Başvurdu semptomları, UAE sonrası komplikasyonlar ve sonraki doğurganlık sonuçları not edildi. Takip süresi 6 ay ile 2,5 yıl arasında değişmektediydi.

PRECIS: UAE for management of symptomatic AVMs following pregnancy is an effective treatment modality.
The inclusion criteria were patients with angiography confirmed AVM who presented with AUB following a pregnancy and who were managed with UAE. Exclusion criteria were patients with no history of antecedent pregnancy before AVM diagnosis; patients in whom angiography report was not available and patients who were not managed with UAE.

After obtaining ethical approval from the Institute Ethics Committee (IEC-660/03.07.2020), data for these cases were retrieved from the hospital records. The patients were followed up telephonically after obtaining verbal consent. Patient’s socio-demographic profile was noted. Detailed history, including presenting symptoms with duration, details of antecedent pregnancy and its outcome, obstetric history, previous menstrual history, investigations, ultrasonography and Doppler findings were extracted from case records.

All patients underwent UAE after discussion regarding their need and feasibility based on the severity of symptoms, failed medical management and ultrasound findings. Pelvic digital subtraction angiography (DSA) was performed in all patients at the time of UAE, which confirmed AVM. UAE was performed under local anesthesia with asepsis. The bilateral common femoral artery was punctured using an 18 gauge needle and a 6F sheath was placed inside the internal iliac artery under fluoroscopic guidance. Embolization was performed using polyvinyl alcohol (PVA) particles, 30% glue injection (Endocryl, Samarth Life Sciences Pvt. Ltd., India) or gelfoam (Spongostan, Ferrosan Medical Devices A/S, Søborg, Denmark), as per availability.

Procedural details such as the type of embolic agent used and intra-procedural difficulty or complications were noted. Post procedure imaging for vascularity and resolution of the lesion was performed after 24 hr. Time taken for the relief of symptoms was noted. The menstrual pattern and any subsequent pregnancy in women keen on conception were determined on telephonic interview. Follow-up period ranged from 6 months to 2.5 years.

Statistical Analysis

Data was analyzed using the statistical package STATA version 12.0 (Texas, USA). Descriptive statistics such as mean, standard deviation and range values were computed for all continuous variables.

**Materials and Methods**

The study was conducted in the Department of Obstetrics and Gynecology, All India Institute of Medical Sciences New Delhi India, a tertiary care hospital, from July 2017 to December 2019.
Results

Total 15 women underwent UAE for AVM, which developed post-pregnancy, over a span of two years. The mean age and parity were 28.4±3.82 years and 1.3 respectively. Nine (60%) patients presented after abortion, including two 2nd trimester abortions, 4 (26.6%) patients presented after normal vaginal delivery and 2 (13.4%) after cesarean section. Symptoms started immediately the following pregnancy in 5/15 (33%) patients and there was no history of curettage. Rest 10 (67%) patients had symptoms following curettage performed for managing antecedent pregnancy complications. Details of patients included in the study are shown in Table 1 and Figure 1. The mean hemoglobin at hospital admission was 8.9±1.97gm/dL. The most common presenting symptom was continuous bleeding per vaginum (BPV) since the antecedent pregnancy in 9/15 (60%) patients, 6/15 (40%) patients had irregular but heavy BPV and four of these required blood transfusions. The mean time interval since symptom onset and UAE was 91±85.7 (30-360) days (Table 1).

The embolic agents used for UAE were PVA particles (300-500 μm diameter) in 2 (13.3%) patients, 30% glue injection in 3 (20%) patients, the combination of PVA with glue injection in 4 (26.6%) and PVA with gelfoam in 6 (40%) patients, as per availability (Table 1). Bilateral UAE was successful in 14/15 (93.3%) patients; with complete symptomatic relief achieved in 3.6±0.97 (3-6) days (mean ± standard deviation, range). One patient required a repeat embolization due to persistent vascularity on Doppler and had symptomatic relief five days after the 2nd UAE. Hence, failure rate in the present study was 6.7%. Figure 2 and Figure 3 show DSA spot images and pre- and post-embolization ultrasound Doppler images, respectively. Procedure related complications were seen in 3 (20%) patients. One patient developed a 2 cm hematoma at the femoral puncture site, which was managed conservatively by pressure bandage and resolved in three days. Two patients developed mild fever with lower abdominal pain and were managed with antipyretics and analgesics. None of the patients had any severe adverse event.

All patients resumed the menstrual cycle in 31.3±5.2 (24-42) days post-procedure. Five (33.3%) patients complained of hypomenorrhoea with mean 1.9±0.7 bleeding days. Three (20%) patients had an increased frequency of cycles (mean-20.6±2.5 days) compared to their previous cycles. Ten out of 15 patients (66.7%) desired conception, of whom 5 (50%) conceived within 13.2±5.1 (6-19) months after UAE. Two patients carried pregnancy to term with no complications, one delivered vaginally and the other underwent cesarean for failed induction. The third patient had preterm cesarean at 34 weeks' gestation done for severe oligohydramnios with fetal growth restriction and had PPH, which was managed...
medically. One patient had spontaneous abortion at 6 weeks gestation and pregnancy is ongoing in another patient who is 13 weeks pregnant (Table 2). However, 3 patients who developed hypomenorhoea tried for conception but none of them conceived within follow-up duration.

**Discussion**

Surgical manipulations such as curettage lead to an increased immune response and angiogenesis, disturbing uterine physiology\(^9,10\). Peitsidis et al.\(^9\) in a systematic review of 91 studies, reported acquired AVM after curettage in 95 of 103 patients with AVM. Obstetric association of AVM even without prior curettage is also reported; proposed mechanism being aberrant regression of the placental bed or abnormal vascular communication after chorionic villi necrosis\(^5\). In a retrospective study by Kim et al.\(^1\), of 19 patients who developed AVM following delivery, approximately a quarter of patients had no history of curettage, which was almost similar to this study, with about 30% patients lacking prior curettage; though in Vilos et al.'s\(^10\) case-series of five patients 60% did not have prior curettage.

In the past, AVMs have been diagnosed incidentally on histopathology after hysterectomy performed for heavy

### Table 1. Overview of patients developing AVM following pregnancy and managed with UAE

| Case | Age (in years) | Parity | Antecedent pregnancy | Symptoms duration at presentation (In days)\(^3\) | Clinical presentation | Medical treatment prior to UAE | Embolic agent | Pregnancy | Interval between UAE and conception (months) |
|------|----------------|--------|-----------------------|----------------------------------|-----------------------|--------------------------------|----------------|-----------|------------------------------------------|
| 1    | 33             | P3L4A1 | Abortion              | 30                               | Continuous BPV        | TA                             | PVA            | Not desired |                                          |
| 2    | 27             | A3     | Abortion              | 60                               | Irregular & HMB       | TA                             | Glue           | Conceived\(^2\) (Caesarean)              | 19           |
| 3    | 22             | PIIIA1 | FTNVD                 | 180                              | Irregular & HMB       | TA                             | Glue           | Not conceived |                                          |
| 4    | 27             | PIIIA2 | Abortion              | 96                               | Continuous BPV        | TA & OCP                      | PVA and glue   | Conceived (Caesarean)                   | 17           |
| 5    | 32             | PIIIA1 | Abortion              | 120                              | Continuous BPV        | TA                             | PVA and glue   | Not conceived |                                          |
| 6    | 30             | PIIIA1 | FTLSCE                | 90                               | Irregular & HMB       | OCP                           | PVA            | Not desired |                                          |
| 7    | 28             | PIIIA1 | Abortion              | 45                               | Continuous BPV        | TA                             | Glue           | Conceived (VD)                          | 13           |
| 8    | 30             | PLLIA3 | Abortion              | 360                              | Irregular & HMB       | TA                             | PVA and glue   | Not conceived |                                          |
| 9    | 24             | PLLOA1 | Abortion              | 60                               | Continuous BPV        | TA                             | PVA and glue   | Conceived\(^3\) (abortion at 8 week)   | 11           |
| 10   | 31             | PLLIA1 | Abortion              | 50                               | Continuous BPV        | TA                             | PVA and Gelfoam | Not conceived |                                          |
| 11   | 27             | PLLA1 | FTNVD                 | 54                               | Continuous BPV        | TA & OCP                      | PVA and Gelfoam | Conceived (ongoing pregnancy-13 weeks) | 6            |
| 12   | 25             | PLLI  | FTNVD                 | 30                               | Continuous BPV        | TA                             | PVA and Gelfoam | Not conceived |                                          |
| 13   | 26             | PLLIA2 | PTVD                  | 30                               | Irregular & HMB       | OCP's                          | PVA and Gelfoam | Not conceived |                                          |
| 14   | 28             | PLLI  | PTLSCE                | 40                               | Continuous BPV        | TA                             | PVA and Gelfoam | Not desired    |                                          |
| 15   | 37             | PLLIA1| Abortion              | 120                              | Irregular & HMB       | TA                             | PVA and Gelfoam | Not desired    |                                          |

1. Onset of symptoms was immediately following pregnancy in 5/15 (33%) patients without history of curettage. Rest 10 (67%) patients had onset of symptoms following curettage done for the management of antecedent pregnancy complications.

2. This patient underwent repeat UAE 48 hours after first UAE due to persistent bleeding and persistent vascularity on Doppler.

3. This patient developed a 2 cm hematoma.

TA: Tranexamic acid, VD: Vaginal delivery, HMB: Heavy menstrual bleeding, PVA: Polyvinyl alcohol, UAE: Uterine artery embolization, AVM: Arterio-venous malformation.
Figure 2. Diagnostic subtraction angiography (DSA) spot images of UAE: A & D showing bilateral hypertrophied uterine arteries supplying the nidus of uterine AVM (curved arrow); B & E showing vessels being embolized sequentially using glue mixed with lipiodol (arrows); C & F showing post embolization angiograms showing non filling of the uterine AVM suggestive of successful embolization.

Figure 3. (A) Pre-embolization ultrasound Doppler image (A) showing bunch of vascular channels within the uterine wall (arrow) suggestive of uterine AVM. (B) Post embolization Doppler image (B) showing complete obliteration of nidus of AVM.
bleeding. The advent of imaging modalities such as colour-Doppler ultrasonography, magnetic resonance imaging, computed tomography and pelvic angiography has made diagnosis easy and early. Pelvic angiography remains the gold standard for diagnosing AVM, though not used routinely as ultrasonography with color Doppler has good detection. In the present study, all cases could be diagnosed with Doppler ultrasound, and confirmed with angiography at the time of UAE.

Treatment options for post-pregnancy AVM remain the same as AVM of other etiologies and include medical treatment, uterine artery sparing UAE or hysterectomy, which is the definitive treatment. Forssman et al. in 1982 reported the first conservative treatment of uterine arteriovenous aneurysm which was occluded at laparotomy by introducing gelfoam into the uterine artery. In a review including a hundred women with iatrogenic AVM after diagnostic curettage and presenting with acute abnormal uterine bleeding, 59% patients underwent UAE, 29% had hysterectomy, 6% responded to methylergometrine, and 6% had a spontaneous resolution. All patients in our study were managed conservatively with UAE and only one patient required the second session of embolization, which is comparable to 5.3% (1/19) reported by Kim et al., though 60% (3/5) patients required repeated embolization in the study by Vilos et al.

The embolic agent most commonly used in patients desiring fertility is gelfoam because of its temporary nature, but no difference is reported in clinical outcome with other embolic agents. Reported complications of the procedure are puncture site superficial hematoma in 0.6-14.8%, uterine artery rupture during manipulation, contrast allergy, adult respiratory distress syndrome and femoral artery hematoma, pseudoaneurysm and arterio-venous fistula. In present study, one patient had puncture site hematoma which was managed with compression. There is concern of diminished ovarian function and consequent amenorrhea and subfertility post-UAE. However, in Peitsidis’ review, most patients resumed normal menstruation within two months and none developed amenorrhea. As in our series, evidence also suggests that the ovarian function might not be affected or, if affected, recovers in young patients undergoing UAE. Fifty percent (5/10) of our patients desiring pregnancy conceived spontaneously within two years of UAE and only one of them had placental insufficiency requiring pre-term delivery. Pregnancy in other patients were uneventful. Two patients were delivered by cesarean due to obstetric indications and other delivered vaginally. Peitsidis et al. reported a pregnancy rate of up to 29% following UAE for AVM with 15 months as mean time to conceive, whereas up to 50% pregnancy rate was reported by Delplanque et al. within mean 38 months from UAE who also studied peak systolic velocity with the success of UAE in AVMs. Post-UAE pregnancy outcomes in a meta-analysis of 227 pregnancies conceived after UAE performed for leiomyoma showed 35.2% risk of abortion, which was three fold higher than controls, 66% caesarean rate; with no increase in preterm delivery rate.

In this study, UAE was successful in the symptomatic management of all fifteen patients presenting with post-pregnancy AVM with no significant complications, and half of the woman desiring pregnancy conceived. Hence, UAE can be offered to young patients with post-pregnancy AVM, though the retrospective nature and small sample size are the limitations of this study.

**Conclusion**

UAE is an effective and safe option for managing symptomatic AVMs developing post-pregnancy in women of reproductive age.

**Ethics**

**Ethics Committee Approval:** After obtaining ethical approval from the Institute Ethics Committee (IEC-660/03.07.2020), data for these cases were retrieved from the hospital records.

**Informed Consent:** Retrospective study.

**Peer-review:** Externally peer-reviewed.

**Authorship Contributions**

Concept: V.K., Sw.S., J.M., S.G., S.S., N.S., S.K., V.D., Design: V.K., Sw.S., J.M., S.G., S.S., N.S., S.K., V.D., Data Collection or Processing: V.K., Sw.S., J.M., S.G., S.S., N.S., S.K., V.D.,
Analysis or Interpretation: V.K., Sw.S., J.M., S.G., S.S., N.S., S.K., V.D., Literature Search: V.K., Sw.S., J.M., S.G., S.S., N.S., S.K., V.D., Writing: V.K., Sw.S., J.M., S.G., S.S., N.S., S.K., V.D.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Kim T, Shin JH, Kim J, Yoon HK, Ko GY, Gwon DI, et al. Management of bleeding uterine arteriovenous malformation with bilateral uterine artery embolization. Yonsei Med J 2014;55:367-73.

2. Kasznica J, Nisar N. Congenital vascular malformation of the uterus in a stillborn: a case report. Hum Pathol 1995;26:240-1.

3. Hoffman MK, Meilstrup JW, Shackelford DP, Kaminski PF. Arteriovenous malformations of the uterus: an uncommon cause of vaginal bleeding. Obstet Gynecol Surv 1997;52:736-40.

4. Kelly S, Belli A, Campbell S. Arteriovenous malformations of the uterus associated with secondary postpartum hemorrhage. Ultrasound Obstet Gynecol 2003;2:602-5.

5. Cura M, Martinez N, Cura A, Dalsaso TJ, Elmerhi F. Arteriovenous malformations of the uterus. Acta Radiol 2009;50:823-9.

6. Timmerman D, Wauters J, Van Calenbergh S, Van Schoubroeck D, MaleuxG, Van Den Bosch T, et al. Color Doppler imaging is a valuable tool for the diagnosis and management of uterine vascular malformations. Ultrasound Obstet Gynecol 2003;2:570-7.

7. Vogelzang RL, Nemcek AA, Skrtic Z, Gorrell J, Lurain JR. Uterine arteriovenous malformations: primary treatment with therapeutic embolization. J Vasc Intervent Radiol 1999;2:517-22.

8. Delplanque S, Le Lous M, Proisy M, Joueidi Y, Bauville E, Rozel C, et al. Fertility, Pregnancy, and Clinical Outcomes after Uterine Arteriovenous Malformation Management. J Minim Invasive Gynecol 2019;26:153-61.

9. Petisis P, Manolakos E, Tsekoura V, Kreinberg R, Schwentner L. Uterine arteriovenous malformations induced after diagnostic curettage: a systematic review. Arch Gynecol Obstet 2011;284:1137-51.

10. Vilos AG, Vilos GA, Hollett-Caines J, Rajakumar C, Garvin G, et al. Uterine artery embolization for uterine arteriovenous malformation in five women desiring fertility: pregnancy outcomes. Hum Reprod 2013;30:1599-605.

11. Manolitsas T, Hurley V, Gilford E. Uterine arteriovenous malformation – a rare cause of uterine haemorrhage. Aust N Z J Obstet Gynaecol 1994;34:197-9.

12. Forssman L, Lundberg J, Scherstén T. Conservative treatment of uterine arteriovenous fistula. Acta Obstet Gynecol Scand 1982;61:85-7.

13. Steinauer JE, Diedrich JT, Wilson MW, Darney PD, Vargas JE, Drey EA. Uterine artery embolization in postabortion hemorrhage. Obstet Gynecol 2008;111:881-9.

14. Chien SC, Tseng SC, Hwa HL, Wei MC. Immediate postpartum haemorrhage caused by rupture of uterine arteriovenous malformation. Aust N Z J Obstet Gynaecol 2007;47:252-4.

15. Vilos GA, Urian R, Chang P, Kozak R. Femoral artery puncture site pseudoaneurysm formation following uterine artery embolization for symptomatic fibroids: a case report. J Obstet Gynaecol Can 2009;31:263-6.

16. Chen LK, Yang BL, Chen KC, Tsai YL. Successful Transarterial Embolization of Uterine Arteriovenous Malformation: Report of Three Cases. Iran J Radiol 2016;13:e15358.

17. Homer H, Saridogan E. Uterine artery embolization for fibroids is associated with an increased risk of miscarriage. Fertil Steril 2010;94:324-30.